689 results on '"Faucher, Catherine"'
Search Results
2. Don de cellules souches hématopoïétiques à partir d’un donneur mineur : cadre réglementaire, information, évaluation de l’aptitude au don et parcours (SFGM-TC)
3. Définition et standardisation des bilans d’histocompatibilité en fonction du parcours du patient et du type de donneur : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) et de la Société Francophone d’Histocompatibilité et Immunogénétique (SFHI)
4. Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC)
5. Impact of COVID-19 pandemic on the use and release of cord blood units facilitated by the French Cord Blood Banks Network: on behalf of the Agency of Biomedicine, Eurocord and the French Society of Bone Marrow Transplant and Cell Therapy (SFGM-TC)
6. Suivi des donneurs apparentés : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
7. Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients
8. Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell–Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients
9. Peripheral Blood Stem Cells versus Bone Marrow for T Cell–Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma
10. Unité de greffe : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
11. HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison
12. Killer Cell Immunoglobulin-Like Receptor–Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell–Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide
13. Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients
14. The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide
15. Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years
16. Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma
17. Haploidentical T Cell–Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen–Matched Related or Unrelated Donor
18. Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen: Outcomes of patients admitted to intensive care unit
19. Prep@Gref: Software Streamlining for the Search for Donors for Hematopoietic Stem Cell Transplantation
20. Poor Outcome with Nonmyeloablative Conditioning Regimen before Cord Blood Transplantation for Patients with High-Risk Acute Myeloid Leukemia Compared with Matched Related or Unrelated Donor Transplantation
21. Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide
22. CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies
23. Impact de la pandémie Covid-19 sur l'activité nationale et les risques afférents à la greffe de cellules souches hématopoïétiques - Une étude rétrospective conjointe de la Société francophone de greffe de moelle et de thérapie cellulaire et de l'Agence de la biomédecine, et une revue de la littérature
24. Response to Immunosuppressive Treatment Predicts Outcome in Patients with Chronic Graft-versus-Host Disease: A Single-Center Analysis of Longitudinal Data
25. Low incidence of chronic GVHD after HLA‐haploidentical peripheral blood stem cell transplantation with post‐transplantation cyclophosphamide in older patients
26. Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study
27. Cellules souches hématopoïétiques, du cordon, embryonnaires et autres : un aperçu réglementaire
28. Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B Cell Lymphoma: Report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire
29. An Extracellular Oligosaccharide Symbiotic Signal Produced by Rhizobium Meliloti
30. Rhizobium meliloti nodulation genes specify the production of an alfalfa-specific sulfated lipo-oligosaccharide signal
31. Impact of COVID-19 pandemic on the use and release of cord blood units facilitated by the French Cord Blood Banks Network: on behalf of the Agency of Biomedicine, Eurocord and the French Society of Bone Marrow Transplant and Cell Therapy (SFGM-TC)
32. Éthique et sociétés : regards croisés
33. Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies
34. Inventory of the GH70 enzymes encoded by Leuconostoc citreum NRRL B-1299 – identification of three novel α-transglucosylases
35. Characterization of a novel dextransucrase from Weissella confusa isolated from sourdough
36. Response of Controlled Cell Load Biofilms to Cold Atmospheric Plasma Jet: Evidence of Extracellular Matrix Contribution
37. Characterization of Glycosyltransferase Activity of Wild-Type Leuconostoc mesenteroides Strains from Bulgarian Fermented Vegetables
38. A dynamic resazurin microassay allowing accurate quantification of cells and suitable for acid-forming bacteria
39. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma
40. Randomized Study of 2 Reduced-Intensity Conditioning Strategies for Human Leukocyte Antigen-Matched, Related Allogeneic Peripheral Blood Stem Cell Transplantation: Prospective Clinical And Socioeconomic Evaluation
41. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation
42. Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma
43. Algorithm based on CMV kinetics DNA viral load for preemptive therapy initiation after hematopoietic cell transplantation
44. CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy
45. Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis on 252 Patients
46. Autologous Peripheral Blood Progenitor-Cell Transplantation versus Autologous Bone Marrow Transplantation for Adults and Children with Non-Leukaemic Malignant Disease: A Randomised Economic Study
47. Sustained response after reduced-intensity conditioning allogeneic stem cell transplantation for patients with relapsed peripheral T-cell non-Hodgkin lymphoma
48. Suivi des donneurs apparentés : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
49. Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma
50. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.